ILK and arteriosclerosis disorder: These observations were further confirmed by the findings of Xu et al. [108] that the mTOR inhibitor, sirolimus, reduced AGE-mediated arteriosclerosis in kidney-transplantation recipients via suppression on the ILK/mTOR pathway.